At present, the available evidence suggests that artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) are effective in treating a large majority of uncomplicated malaria cases in Cameroon.

Data on the efficacy, safety and tolerability of artemisinin-based combination therapies, including the first-line drugs ASAQ and AL are insufficient to draw a more solid conclusion in Cameroon.

Surveillance of antimalarial drug efficacy and safety should be reinforced to detect possible future changes in parasite sensitivity to ACT, and more randomised clinical trials should be conducted, including novel ACTs.